Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic

On May 1, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to allow use of the antiviral drug remdesivir to treat patients with severe coronavirus disease-2019 (COVID-19). Remdesivir is an investigational drug studied in clinical trials for COVID-19 and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sarah, DeBruin, Debra A., Leider, Jonathon P., Sederstrom, Nneka, Lynfield, Ruth, Baker, Jason V., Kline, Susan, Kesler, Sarah, Rizza, Stacey, Wu, Joel, Sharp, Richard R., Wolf, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mayo Foundation for Medical Education and Research 2020
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305893/
https://www.ncbi.nlm.nih.gov/pubmed/32861338
http://dx.doi.org/10.1016/j.mayocp.2020.06.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305893/
https://www.ncbi.nlm.nih.gov/pubmed/32861338
http://dx.doi.org/10.1016/j.mayocp.2020.06.016

Ejemplares similares